Search
Tacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalIt reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. … Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection.
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalIt was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings.
Ensitrelvir
go.drugbank.com/drugs/DB18834ApprovedInvestigationalEnsitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).
Robenidine
go.drugbank.com/drugs/DB11542ExperimentalVet approvedFarmers alternate the use of robenidine with other antimicrobial agents in order to maintain effectiveness by slowing the development of antimicrobial resistance.
Carfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treat...
Calcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceuticalIn addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways … It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to [DB00169] (vitamin D3) in the skin, which is then converted
Products: K-LAMInsulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalUse of the higher concentrated Toujeo as compared to Lantus results in slightly different pharmacokinetics, with a later onset (up to 6 hours) and duration of action (up to 30 hours). … Insulin glargine is also available as the biosimilar, or "follow-on" product, Basaglar in the US and as Abasaglar in the EU.
Mixtures: SOLİQUA SOLOSTAR 100 U/ML + 33 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEM, SOLİQUA SOLOSTAR 100 U/ML + 50 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEMProducts: LANTUS ® 100 U / ML, Insulin glargine U-300Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalIn early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for
Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigational[A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.
Dexfenfluramine
go.drugbank.com/drugs/DB01191ApprovedIllicitWithdrawnFor a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.